Dauntless Investment Group LLC Invests $1.07 Million in Myomo, Inc. (NYSEAMERICAN:MYO)

Dauntless Investment Group LLC purchased a new position in shares of Myomo, Inc. (NYSEAMERICAN:MYO - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 166,196 shares of the company's stock, valued at approximately $1,070,000. Myomo accounts for about 1.1% of Dauntless Investment Group LLC's portfolio, making the stock its 7th biggest position. Dauntless Investment Group LLC owned about 0.55% of Myomo as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of MYO. Barclays PLC acquired a new position in Myomo during the 3rd quarter valued at about $36,000. Jane Street Group LLC acquired a new position in shares of Myomo during the third quarter valued at approximately $65,000. Russell Investments Group Ltd. bought a new stake in Myomo during the fourth quarter worth approximately $229,000. AIGH Capital Management LLC lifted its position in Myomo by 21.7% in the fourth quarter. AIGH Capital Management LLC now owns 3,381,567 shares of the company's stock worth $21,777,000 after purchasing an additional 602,719 shares during the period. Finally, Perkins Capital Management Inc. bought a new position in Myomo during the 4th quarter valued at $483,000. 44.99% of the stock is owned by institutional investors and hedge funds.

Myomo Stock Performance

Shares of Myomo stock traded down $0.06 during midday trading on Tuesday, reaching $4.75. 85,894 shares of the company's stock traded hands, compared to its average volume of 346,265. Myomo, Inc. has a 52 week low of $2.76 and a 52 week high of $7.17. The firm has a 50 day moving average of $4.86. The stock has a market capitalization of $143.69 million, a P/E ratio of -20.74 and a beta of 1.68.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Ascendiant Capital Markets lifted their target price on Myomo from $9.00 to $11.00 and gave the stock a "buy" rating in a report on Monday, March 17th. Craig Hallum lifted their target price on shares of Myomo from $9.00 to $11.00 and gave the company a "buy" rating in a research note on Tuesday, March 11th. HC Wainwright upped their price target on shares of Myomo from $7.50 to $9.50 and gave the stock a "buy" rating in a research note on Wednesday, March 12th. Finally, Alliance Global Partners restated a "buy" rating on shares of Myomo in a research note on Tuesday, March 11th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Myomo presently has an average rating of "Buy" and an average price target of $9.75.

Insider Buying and Selling at Myomo

In other Myomo news, Director Thomas F. Kirk purchased 7,400 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was bought at an average cost of $5.00 per share, for a total transaction of $37,000.00. Following the completion of the acquisition, the director now directly owns 255,933 shares in the company, valued at $1,279,665. This represents a 2.98 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Harry Kovelman sold 30,000 shares of the firm's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $5.50, for a total transaction of $165,000.00. Following the completion of the sale, the insider now owns 97,973 shares in the company, valued at approximately $538,851.50. The trade was a 23.44 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.54% of the company's stock.

About Myomo

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living.